Stockreport

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

89bio, Inc.  (ETNB) 
Last 89bio, inc. earnings: 3/18 04:05 pm Check Earnings Report
PDF SAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercializatio [Read more]